mediaire builds AI-powered diagnostic solutions for MRI imaging, including products mdbrain, mdprostate, and mdknee, designed for seamless integration into clinical workflows. Its software provides automated decision support to improve diagnostic accuracy and optimize workflow efficiency. The company reports deployment in over 350 hospitals and clinics across Europe and daily use by radiologists in hundreds of institutions. mediaire says the funding will let it expand its AI portfolio beyond brain, prostate, and knee diagnostics to additional MRI applications. The company highlights partnerships with university hospitals and industry players such as Bayer/Calantic, Sectra, deepc, and radiology chains including Med360, Evidia, Starvision, and RIMED/UNILABS. With a stronger product pipeline and international presence, mediaire is positioning to scale its clinical footprint and commercial reach. mediaire develops mdbrain, an AI- and deep-learning-powered software that performs quantitative MRI analysis to accelerate brain-volume quantification and detect brain lesions. The software integrates into customers' local IT systems, providing an objective second opinion within minutes while emphasizing data protection. mediaire is certified per DIN EN ISO 13485:2016, which enables commercialization of mdbrain in Europe with a CE mark. In December 2020 an international investor pool including High‑Tech Gründerfonds (HTGF), primeCROWD and LIFTT invested approximately €2 million in a seed capital increase to support growth. The company plans European expansion beginning in 2021 (after initial deployments in Germany, Switzerland and Austria in 2020), further international expansion by 2023, and a product portfolio extension into areas such as knee and prostate. Proceeds will be used to scale sales & marketing, build a commercial network, further develop the product range and pursue upselling; headcount is expected to reach about 150 employees by 2025. mediaire builds mdbrain, a software-as-a-service that automates time-consuming radiology tasks and quantifies brain regions from MRI scans to support dementia diagnostics. The product was developed after a radiologist requested automated evaluation of brain regions and a working prototype validated demand in practice. The company charges most customers roughly €10–15 per analysis, with pricing dependent on monthly volume, and offers free trial access plus complimentary installation and service. mediaire positions its solution to reduce quality losses from radiologists’ rising image workloads and extremely short per-image review times. The startup has participated in the Science4Life business-plan competition and employs 16 people. Financially, it has already received funding support as it prepares a Series A round targeted for 2020. mediaire develops a fully automated software solution that delivers precise examination results and diagnostic suggestions within minutes to aid early detection of neurodegenerative diseases such as Alzheimer’s and Multiple Sclerosis. The system uses deep learning methods to detect and evaluate biomarkers, designed to achieve high-quality results with only a limited number of annotated data. The software is fully integrated into the IT system of the radiological practice so patient data never leaves the practice. This integration enables radiologists to provide diagnostic support while the patient is still in the practice. The company was founded in April 2018 and is based in Berlin, Germany. Financially, mediaire raised a six-digit euro funding round backed by High‑Tech Gründerfonds and a group of private investors represented by Sebastian Burian.

Total raised

$18M

Funding rounds

4

Latest round

Equity

Latest activity

Nov 2024